Form 4: Neogenomics Executive Melody Harris Reports Changes in Beneficial Ownership
SEC Form 4
Melody Harris, Chief Operations Officer, President, and Head of Informatics at Neogenomics, reports changes in her beneficial ownership of company stock due to tax obligations and ESPP acquisitions.
Summary
- Melody Harris, a key executive at Neogenomics, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- On January 1, 2025, Ms. Harris surrendered 7,070 shares of common stock to cover tax obligations related to the vesting of restricted stock.
- Ms. Harris's holdings include 102,820 shares of common stock, which includes 1,589 shares acquired through the Employee Stock Purchase Plan (ESPP) since her last filing.
- Ms. Harris also holds multiple stock options, restricted stock units, and performance stock units with varying vesting schedules and performance criteria.
- These equity awards were granted on various dates, including January 1, 2023, May 11, 2023, February 23, 2024, and May 2, 2024.
- The performance stock units' vesting is contingent upon achieving certain share growth and revenue growth goals.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing, indicating routine transactions related to executive compensation. It doesn't contain information that would significantly sway investor sentiment positively or negatively.
Positives
- The executive's participation in the Employee Stock Purchase Plan (ESPP) indicates confidence in the company's future.
- The vesting of restricted stock and performance stock units aligns the executive's interests with those of the shareholders.
Future Outlook
The vesting of stock options and restricted stock units in the future is contingent upon continued service with the company.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is typical for executives receiving equity compensation.
Comparison to Industry Standards
- Equity compensation is a common practice in the biotech and diagnostics industries to incentivize executives and align their interests with shareholders.
- Companies like Exact Sciences and Guardant Health also utilize stock options and restricted stock units as part of their executive compensation packages.
- The vesting schedules and performance criteria outlined in this filing are generally consistent with industry standards.
Stakeholder Impact
- The vesting of equity awards aligns the executive's interests with those of the shareholders, potentially leading to increased focus on long-term value creation.
- The ESPP allows employees to purchase company stock at a discounted rate, fostering a sense of ownership and shared success.
Key Dates
| Date | Description |
|---|---|
| 01/01/2023 | Ms. Harris was granted 201,613 stock options. |
| 05/11/2023 | Ms. Harris was granted 39,683 stock options, 21,204 restricted stock units, and 21,204 performance stock units. |
| 02/23/2024 | Ms. Harris was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/02/2024 | Ms. Harris was granted 19,984 stock options, 11,939 restricted stock units, and 11,939 performance stock units. |
| 01/01/2025 | Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the January 1, 2025 vesting of restricted stock. |
| 01/03/2025 | Date of signature by Attorney-in-Fact. |
| 05/11/2026 | Expiration date for performance stock units granted on May 11, 2023. |
| 02/23/2027 | Expiration date for performance stock units granted on February 23, 2024. |
| 05/02/2027 | Expiration date for performance stock units granted on May 2, 2024. |
| 01/01/2030 | Expiration date for stock options granted on January 1, 2023. |
| 05/11/2030 | Expiration date for stock options granted on May 11, 2023. |
| 02/23/2034 | Expiration date for stock options granted on February 23, 2024. |
| 05/02/2034 | Expiration date for stock options granted on May 2, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.